

AR 226 - 3310

TRADE SECRET*Study Title*


H-25357: Biopersistence Screening
10-Dose Oral Gavage Study in Rats

Laboratory Project ID: DuPont-11557

AUTHOR: Carol Finlay, B.A.

STUDY COMPLETED ON: November 26, 2003

PERFORMING LABORATORY: E.I. du Pont de Nemours and Company
Haskell Laboratory for Health and Environmental Sciences
Elkton Road, P.O. Box 50
Newark, Delaware 19714-0050




Company Sanitized. Does not contain TSCA CBI

CERTIFICATION

We, the undersigned, declare that this report provides an accurate evaluation of data obtained from this study.

Reviewed by:



Paul M. Hinderliter, Ph.D.
Research Toxicologist

26-Nov-2003

Date

Issued by Study Director:



Carol Finlay, B.A.
Staff Toxicologist

26-Nov-2003

Date

Company Sanitized. Does not contain TSCA CBI

TABLE OF CONTENTS

	Page
CERTIFICATION	2
LIST OF TABLES	4
LIST OF FIGURES	4
LIST OF APPENDICES	5
STUDY INFORMATION	6
STUDY PERSONNEL	8
SUMMARY	9
INTRODUCTION	11
MATERIALS AND METHODS	11
A. Test Substance and Positive Controls	11
B. Test Species	11
C. Animal Husbandry	11
D. Quarantine and Pretest	12
E. Study Design	13
F. Assignment to Groups and Study Start	13
G. Dosing Material Preparation and Administration	13
H. Body Weights	14
I. Mortality and Clinical Observations	14
J. Collection and Analysis of Blood, Livers, and Fat	14
K. Treatment of Fluorine Data	15
L. Statistical Analyses	15
RESULTS AND DISCUSSION	16
A. In-Life Toxicology	16
B. Liver Weights	16
C. Fluorine Data	17
CONCLUSIONS	18
RECORDS AND SAMPLE STORAGE	19
TABLES	20
FIGURES	27
APPENDICES	38

Company Sanitized. Does not contain TSCA

LIST OF TABLES

	Page
1. MEAN BODY WEIGHTS.....	21
2. MEAN BODY WEIGHT GAINS.....	22
3. MEAN BODY AND LIVER WEIGHTS.....	23
4. MEAN BLOOD FLUORINE LEVELS.....	24
5. MEAN BLOOD FLUORINE CONCENTRATION NORMALIZED TO DOSE.....	24
6. MEAN LIVER FLUORINE LEVELS.....	25
7. MEAN LIVER FLUORINE CONCENTRATION NORMALIZED TO DOSE.....	25
8. MEAN FAT FLUORINE LEVELS.....	26
9. MEAN FAT FLUORINE CONCENTRATION NORMALIZED TO DOSE.....	26

LIST OF FIGURES

	Page
1. MEAN BODY WEIGHTS.....	28
2. COMPARISON OF MEAN RELATIVE LIVER WEIGHTS: TEST SUBSTANCE AND NEGATIVE CONTROL.....	29
3. COMPARISON OF MEAN RELATIVE LIVER WEIGHTS: TEST SUBSTANCE AND POSITIVE CONTROLS.....	30
4. MICROMOLAR EQUIVALENTS IN RAT BLOOD.....	31
5. NORMALIZED H-25357 AND POSITIVE CONTROL BLOOD AUCINF/D RESULTING FROM A 10-DAY ORAL GAVAGE.....	33
6. MEAN LIVER FLUORINE CONCENTRATION NORMALIZED TO DOSE.....	34
7. COMPARISON OF RELATIVE LIVER WEIGHT AND MEAN LIVER FLUORINE CONCENTRATION FOR H-25357 AND NEGATIVE CONTROL.....	35
8. MEAN FAT FLUORINE CONCENTRATION NORMALIZED TO DOSE.....	36
9. COMPARISON OF MEAN BLOOD, MEAN LIVER, AND MEAN FAT FLUORINE CONCENTRATION NORMALIZED TO DOSE.....	37

Company Sanitized. Does not contain TSCA CBI

LIST OF APPENDICES

	Page
A. INDIVIDUAL BODY WEIGHTS.....	39
B. INDIVIDUAL CLINICAL OBSERVATIONS.....	49
C. TERMS AND CALCULATIONS FACTORS INFLUENCING INTERPRETATION OF KINETIC ANALYSIS	63
D. INDIVIDUAL FLUORINE LEVELS IN BLOOD	67
E. INDIVIDUAL FLUORINE LEVELS IN LIVER	74
F. INDIVIDUAL FLUORINE LEVELS IN FAT	78

STUDY INFORMATION

Test Substance

Substance Tested: [REDACTED]

Synonyms/Codes: H-25357
[REDACTED]

Submitter's Notebook Number(s): [REDACTED]

Haskell Number: 25357

CAS Registry Number: [REDACTED]

Composition: [REDACTED]

Purity: [REDACTED]

Known Impurities: [REDACTED]

Positive Control

Substance Tested: Potassium perfluoroalkyl sulfonate

Synonyms/Codes: H-24019
[REDACTED]


PFOS
[REDACTED]

Haskell Number: 24019

Company Sanitized. Does not contain TSCA CBI

STUDY INFORMATION (Continued)

Composition:



Known Impurities:



Positive Control

Substance Tested: Octanoic acid, pentadecafluoro-, ammonium salt


Synonyms/Codes: • H-24020



- C-8
- Perfluorooctanoate, ammonium salt
- APFO
- Ammonium perfluorooctanoate

Haskell Number: 24020

Composition:



Known Impurities:



Sponsor: E.I. du Pont de Nemours and Company
Wilmington, Delaware 19898
U.S.A.

Study Initiated/Completed: October 10, 2002 / (see report cover page)

Company Sanitized. Does not contain TSCA CBI

STUDY PERSONNEL

Study Director: Carol Finlay, B.A.

Management: Judith C. Stadler, Ph.D., D.A.B.T.
Scott E. Loveless, Ph.D.

Primary Technician: James C. Mackay II

Fluorine Data Analysis: Paul M. Hinderliter, Ph.D.

Management: Matthew S. Bogdanffy, Ph.D., D.A.B.T.

Toxicology Report Preparation: Sean M. Callaghan, B.A.

Management: Nancy S. Selzer, M.S.

Laboratory Veterinarian: Thomas W. Mayer, D.V.M., A.C.L.A.M.

Company Sanitized. Does not contain TSCA CBI

Company Sanitized. Does not contain TS

SUMMARY

The objective of this study was to evaluate the potential for H-25357 to be absorbed and to accumulate in a mammalian system. Two groups of 5 male rats each were dosed by gavage with 1000 mg/kg/day of H-25357 for 10 consecutive days. One group was sacrificed on Day 10, and the other group was maintained without dosing for an additional 84 days. Blood was collected on test days 1, 5, 10, 13, 24, 52, and 94. Livers and fat were collected at sacrifice. Body weights and clinical signs were recorded throughout the dosing and recovery periods. Additionally, a negative control of deionized water and 2 positive controls, H-24019 (10 mg/kg/day) and H-24020 (20 mg/kg/day), were tested as described for H-25357. Blood, liver, and fat samples were analyzed for total fluorine content to determine test substance absorption and retention in these tissues.

No deaths occurred, and no clinical signs attributed to the test substance were observed. The mean body weight gains of rats dosed with H-25357 were higher than the negative control rats during the dosing and recovery periods. Mean body weight gains of rats dosed with the positive control materials were lower during the dosing period than the weight gains of rats dosed with the test substance. During the recovery period, the mean body weight gain of rats dosed with the positive control material H-24019 was lower than the weight gain of rats dosed with the test substance. The mean body weight gain of rats dosed with the other positive control material, H-24020, was higher than the weight gain of rats dosed with the test substance.

For the purpose of comparing absorption and retention of the test substance to the positive controls, all doses were normalized on a molar basis. The total fluorine in each tissue was considered as a percentage of the fluorine delivered in the administered dose, and all units were expressed as μM equivalents. As a measure of total dose in the blood, an area under the curve (estimated to infinity) was calculated for the test substance and positive controls. The AUCINF/D for the fluorine component of H-25357 was 8.61×10^2 , compared to AUCINF/D values of 5.22×10^5 and 8.15×10^4 for H-24019 and H-24020, respectively. This parameter indicated a total dose in blood that was much less for H-25357, the test substance, than for the positive controls. There was no detectable fluorine in the blood on days 52 and 94 in rats dosed with the test substance.

The mean relative liver weight (liver/body weight) of rats dosed with H-25357 was 24% higher than the negative control rats on day 10. By day 94, the mean relative liver weight of rats dosed with H-25357 was similar to the negative control. The mean relative liver weight of rats dosed with H-24019 was 41% higher and for H-24020 was 93% higher on day 10 than the negative control group. By day 94, the mean relative liver weights of rats dosed with H-24019 and H-24020 were similar to the negative control group. Therefore, liver weights of rats dosed with the test substance were higher than the negative controls at the end of the dosing period but were similar to the negative controls at the end of the recovery period.

The concentration of fluorine in the livers from rats dosed with H-25357 was 114.94 μM equivalents on day 10 and 6.96 μM equivalents on day 94. On the last day of dosing, the mean

μM equivalent concentrations of fluorine in the livers of rats dosed with the positive control materials were approximately 42-fold (H-24019) and 8-fold (H-24020) greater than values in rats treated with the test substance. By day 94, the fluorine concentrations in μM equivalents were approximately 186x and 2x the fluorine concentration in rats treated with H-25357. Therefore, rats treated with H-24019 or H-24020 absorbed and retained considerably more fluorine in the liver than rats treated with the test substance, H-25357.

The fluorine concentration in the fat from rats dosed with the test substance was 107.79 μM equivalents on day 10 and 13.59 μM equivalents on day 94. The fluorine concentration in μM equivalents of one of the positive control materials, H-24019, was approximately 2x higher than H-25357 on day 10. The fluorine concentration of the test substance, H-25657, was approximately 2x higher on day 10 than the fluorine concentration of the other positive control material, H-24020. By day 94, the fluorine concentration of the positive control, H-24019, was similar to the fluorine concentration in rats treated with the test substance, H-25357. There was no detectable fluorine by day 94 in the fat from rats dosed with the positive control H-24020.

Under the conditions of this study, fluorine was evident in the blood during the period of dosing with H-25357, but was quickly eliminated. The amounts of fluorine in the livers and fat from rats dosed with the test substance were higher than levels in the blood, and the results indicate that there was evidence of some retention of fluorine in the liver and fat. Fluorine levels in the blood and liver were lower than levels in rats dosed with the positive controls, H-24019 and H-24020. Fluorine levels in the fat were lower at day 10 than levels in rats dosed with the positive control H-24019 but higher than the positive control H-24020. At day 94, fluorine levels in the fat were similar to or higher than levels in the positive controls.

INTRODUCTION

The objective of this study was to define the potential of H-25357 to be absorbed and to bioaccumulate in a mammalian system, as indicated by analytical determination of total fluorine in blood, liver, and fat. The test substance was compared to 2 positive controls that were materials previously shown to bioaccumulate in mammals. The daily dosage of 1000 mg/kg for the test substance was selected based on existing toxicity information.

MATERIALS AND METHODS

A. Test Substance and Positive Controls

The test substance, H-25357, was supplied by the sponsor as an amber liquid. The positive controls, H-24019 and H-24020, were supplied by the sponsor as white solids. The test substance and positive controls appeared to be stable under the conditions of the study. No evidence of instability, such as a change in color or physical state, was observed.

B. Test Species

Male Crl:CD[®](SD)IGS BR rats were received from Charles River Laboratories, Inc., Raleigh, North Carolina. The Crl:CD[®](SD)IGS BR rat was selected on the basis of extensive experience with this strain and its suitability with respect to longevity, hardiness, and low incidence of spontaneous diseases.

C. Animal Husbandry

1. Housing Environment

Rats were housed singly in stainless steel, wire-mesh cages suspended above cage boards. Animal rooms were maintained on an approximate 12-hour light/dark cycle (fluorescent light) and at a temperature of $23 \pm 1^{\circ}\text{C}$ and a relative humidity of $50 \pm 10\%$.

2. Feed and Water

Tap water was provided *ad libitum*. All rats were fed PMI[®] Nutrition International, LLC Certified Rodent LabDiet[®] 5002 chow. The feed is guaranteed by the manufacturer to meet specified nutritional requirements and to be free of specified contaminants.

Company Sanitized. Does not contain TSCA C

3. Identification

Each rat was assigned a unique identification number which was recorded on a card affixed to the cage. The last 3 digits of the number were tattooed on the tail of each rat.

4. Health Monitoring Program

As specified in the Haskell Laboratory animal health and environmental monitoring program, the following procedures are performed periodically to ensure that contaminant levels are below those that would be expected to impact the scientific integrity of the study:

- Water samples are analyzed for total bacterial counts, and the presence of coliforms, lead, and other contaminants.
- Feed samples are analyzed for total bacterial, spore, and fungal counts.
- Samples from freshly washed cages and cage racks are analyzed to ensure adequate sanitation by the cagewashers.

Certified animal feed is used, guaranteed by the manufacturer to meet specified nutritional requirements and not to exceed stated maximum concentrations of key contaminants, including specified heavy metals, aflatoxin, chlorinated hydrocarbons, and organophosphates. The presence of these contaminants below the maximum concentration stated by the manufacturer would not be expected to impact the integrity of the study.

The animal health and environmental monitoring program is administered by the attending laboratory animal veterinarian. Evaluation of these data did not indicate any conditions that affected the validity of the study.

D. Quarantine and Pretest

Upon arrival at Haskell Laboratory, the rats were removed from shipping cartons and quarantined for 6 days. The rats were weighed 3 times during the pretest period and examined daily for any clinically apparent signs of disease or injury. The rats were observed daily for mortality and signs of illness, injury, or abnormal behavior.

On the bases of acceptable body weight gains and freedom from clinically apparent signs of disease or injury, the rats were released from quarantine by the designee of the laboratory animal veterinarian.

Company Sanitized. Does not contain TSCA CBI

E. Study Design

Substance	Vehicle	Dosage (mg/kg)	Number of Animals
Negative Control Deionized water	Not applicable	0	10
Positive Controls H-24019	Acetone/Corn Oil	10	10
H-24020	Acetone/Corn Oil	20	10
Test Substance H-25357	None	1000	10

F. Assignment to Groups and Study Start

After the quarantine period, the rats were selected on the bases of adequate body weight gain, and freedom from any clinical signs of disease or injury. The selected rats were arbitrarily assigned to each group.

After assignment to groups, each rat was housed individually. The rats were 7 weeks of age at the time of dosing. Dosing began on test day 1.

Rats that were not assigned to the study were released for other laboratory purposes, or were sacrificed by carbon dioxide asphyxiation and discarded without pathology evaluation.

G. Dosing Material Preparation and Administration

1. Test Substance

H-25357 was administered neat. The amount of test substance each rat received was based on the body weight collected on each day of dosing. The test substance was stirred on a magnetic stir plate throughout the dosing procedure to maintain homogeneity.

2. Positive Controls

It was necessary to dissolve H-24019 and H-24020 in acetone before suspending them in corn oil. The ratio of acetone to corn oil was 20:80. The amount each rat received was based on the body weight collected on each day of dosing and the suspension concentration. The rats were dosed at a volume 1 mL/100 g of body weight. The dosing preparations were stirred on a magnetic stir plate throughout the dosing procedure to maintain homogeneity.

3. Negative Control

Deionized water was chosen as the negative control. The rats were dosed at a volume of 1 mL/100 g of body weight. These rats were dosed in a separate room from the rats dosed with the test substance or positive controls.

Company Sanitized. Does not contain TSCA

H. Body Weights

All rats were weighed on each day of dosing and weekly during the recovery period.

I. Mortality and Clinical Observations

Cage-site examinations to detect moribund or dead rats and abnormal behavior and appearance among rats were conducted at least once daily throughout the study. At every weighing, each rat was individually handled and examined for abnormal behavior and appearance.

J. Collection and Analysis of Blood, Livers, and Fat

At time points selected for blood sampling other than sacrifice days, approximately 1 mL of blood was collected into EDTA tubes from the orbital sinus of each rat. Rats designated for sacrifice were euthanized by carbon dioxide anesthesia and exsanguination and blood, livers, and fat were collected according to the following schedules:

Group	Dosing Days	Tissue Collected	Sampling Time
I	1-10	Blood	Test day 1 (2 hours post dosing)
I	1-10	Blood	Test day 5 (2 hours post dosing)
I	1-10	Blood, Liver, and Fat	Test day 10 at sacrifice (2 hours post dosing)
III	1-10	Blood	Test day 13
III	1-10	Blood	Test day 24
III	1-10	Blood	Test day 52
III	1-10	Blood, Liver, and Fat	Test day 94

As much blood as possible was collected into EDTA tubes at sacrifice. The livers and fat were weighed. The fat weights were used for the calculation of fluorine levels. The liver weights were used for the calculation of fluorine levels and for the calculation of liver weight relative to total body weight. The blood from all rats was refrigerated and the livers and fat were frozen. The blood, livers, and fat were appropriately packaged and shipped to Jackson Laboratory, Deepwater, New Jersey where they were analyzed for total fluorine. The liver and fat samples remained frozen during shipping.

The total fluorine content of the blood and tissue samples was determined using a Wickbold torch combustion method, followed by analysis with a fluoride ion selective electrode. The samples were decomposed or volatilized in the presence of wet oxygen and swept through an oxy-hydrogen flame in a closed quartz apparatus. The combustion products were collected in an aqueous absorbing solution and analyzed with a fluoride ion selective electrode. Kinetic analysis of the data received (ppm F in each sample) was performed by Haskell Laboratory personnel for evaluation of fluorine biopersistence.

Company Sanitized Does not contain TSCA ORR

K. Treatment of Fluorine Data

Since the test substance and positive controls had different toxicity profiles, it was not possible to administer a uniform mg/kg dose for all test materials. Properly conducted kinetic comparisons in situations with varied doses required the use of a normalized dose. The dose-normalization was conducted in μ molar units to accommodate test material molecular weight differences and was adjusted to an arbitrary normalized dose of 0.1 mmoles/kg.

H-24019 and H-24020 were used as positive controls and a dosing diluent was used as the negative control. The percent of fluorine and molecular weight of the test substance and positive controls were used as provided by the sponsor. The measured total fluorine values were used as received (ppm F) from Jackson Laboratory. For the Wickbold torch method, the background fluorine level is 0.2 ppm. This is the limit of detection (LOD) of this method and was subtracted from each sample. The limit of quantification (LOQ) for this method is 0.5 ppm, and any values listed as less than 0.5 ppm were excluded from further treatment.

Since the dosages and molecular weight for positive controls and test material differed, the data were converted from a mass to a molar basis. In addition, the data were standardized to a single reference dose to allow comparison between compounds of differing fluorine content. The doses were first converted from a mg of test material basis to millimoles of fluorine. Raw fluoride ion data (ppm F) were then normalized to a 0.1 millimole dose of active component. Finally the molar dosage and normalized concentration were combined to yield the μ molar (μ M) equivalents of active component in the tissue. Detailed calculations can be found in Appendix C. The μ M equivalents can be compared across compounds provided the considerations listed in Appendix C are observed.

Noncompartmental analysis was conducted on fluorine data derived from rats dosed with H-25357 and the positive controls using WinNonlin Version 4.0 software (Pharsight Corp, Mountain View, CA). WinNonlin software provided a means of computing derived pharmacokinetic parameters from experimental data. All analysis was calculated using the μ M equivalent in blood data.

The maximum observed concentration in blood was C_{max} (μ M equivalent). Biopersistence was assessed by quantifying terminal elimination blood half-life ($T_{1/2}$, days). The points included in determination of the $T_{1/2}$ were selected manually and included only points after apparent log-linear elimination was achieved. Internal exposure was determined by calculating the blood area-under-the-curve (AUC). AUC, which is simply the integral of blood concentration over time, is the most common means for expressing internal dose. With the calculated half-life, the AUC can be extrapolated to infinity (AUCINF) to reflect the elimination of the compound. AUCINF normalized to dose (AUCINF/D) can be used to compare the relative exposures of different compounds and dosages.

L. Statistical Analyses

Descriptive statistics (e.g. mean, standard deviation) were used.

RESULTS AND DISCUSSION

A. In-Life Toxicology

(Tables 1-2, Figure 1, Appendices A-B)

No deaths occurred. Hair loss observed in two rats during the study was considered to be incidental and not test substance-related. The mean body weight gains of rats dosed with the test substance were higher than the negative control during the dosing and recovery periods. The mean body weight gains of the rats dosed with the positive control materials were lower during the dosing period than the weight gain of rats dosed with the test substance. During the recovery period, the mean body weight gain of rats dosed with the positive control material H-24019 was lower than the weight gain of rats dosed with the test substance. The mean body weight gain of rats dosed with the other positive control material, H-24020, was higher than the weight gain of rats dosed with the test substance.

B. Liver Weights

(Table 3, Figures 2, 3, and 7)

1. Test Substance

The mean relative liver weight (liver/body weight) of rats dosed with H-25357 was 24% higher than the negative control rats on day 10. By day 94, the mean relative liver weight of rats dosed with H-25357 was similar to the negative control.

2. Positive Controls

The mean relative liver weight of rats dosed with one of the positive controls, H-24019, was 12% higher on days 10 than the liver weight of rats dosed with the test substance, H-25357. By day 94, the weights were similar.

The mean relative liver weight of rats dosed with the other positive control, H-24020, was 52% higher at day 10 than the liver weight of rats dosed with H-25357. By day 94, the weights were similar.

The mean relative liver weight of rats dosed with H-24019 was 38% higher at day 10 than the negative control group. By day 94, the mean relative liver weight of rats dosed with H-24019 was similar to the negative control group. The mean relative liver weight of rats dosed with H-24020 was 88% higher on day 10 than the negative control group. By day 94, the weights were similar.

Therefore, the relative liver weights of rats dosed with the test substance, H-25357, were higher than the negative controls at the end of the dosing period but were similar to the negative controls at the end of the recovery period.

Company Sanitized. Does not contain TSCA CBI

C. Fluorine Data

(Tables 4-9, Figures 4-9, Appendices C-F)

1. Factors Influencing Interpretation of Analysis

The data used in the kinetic analysis were derived from a limited screen, and therefore several caveats and considerations are important. A couple of considerations of particular importance are (1) a single dose level was used and kinetics may or may not be linear, (2) the kinetics apply only to blood, (3) steady-state may not have been achieved and (4) the sample size is low and may impact calculation of the terminal half-life. A more complete list of considerations is shown in Appendix C.

2. Positive Controls

The positive controls were H-24019 and H-24020. The H-24019 and H-24020 normalized μM equivalents in rat blood continued to rise throughout the dosing period and may not have reached steady-state (Figure 4A and 4B). The C_{max} for H-24019 was $1043.08 \pm 54.57 \mu\text{M}$ equivalents (mean $\pm$ S.D.) with a terminal half-life of 42.2 days. The C_{max} for H-24020 was $541.45 \pm 50.37 \mu\text{M}$ equivalents (mean $\pm$ S.D.) with a terminal half-life of 15.1 days. For each of the positive controls, blood was sampled at 7 time points throughout the study, with only 4 of them occurring post-dose. The small sample size and analytical variability should be taken into account when using the derived terminal half-life for comparative purposes. The total internal exposure resulting from a normalized dose was described by AUCINF/D and was the basis for comparison between positive controls and the test substance. The AUCINF/D for the fluorine component was 5.22×10^5 for H-24019 and 8.15×10^4 for H-24020.

The concentrations of fluorine in the livers on day 10 from rats dosed with the positive control materials were 4802.15 and 866.67 μM equivalents for H-24019 and H-24020, respectively. By day 94, the concentrations were 1292.92 and 17.10 μM equivalents.

The concentrations of fluorine in the fat on day 10 from rats dosed with the positive control materials were 194.46 and 57.25 μM equivalents for H-24019 and H-24020, respectively. By day 94, the concentration of fluorine in the fat from rats dosed with H-24019 was 15.38 μM equivalents. There was no detectable fluorine by day 94 in the fat from rats dosed with H-24020.

3. Test Substance

The H-25357 normalized μM equivalents in rat blood rose rapidly and appears to have reached reach steady-state (Figure 4C). The C_{max} for H-25357 was $15.74 \pm 0.88 \mu\text{M}$ equivalents (mean $\pm$ SD). Terminal half-life could not be accurately calculated because no samples on days 52 and 94 were above the limit of quantification. Blood was sampled at seven time points throughout the study, with only four of them occurring post-dose. The small sample size and analytical variability should be taken into account when using the derived terminal half-life for comparative purposes. The total internal exposure resulting from a normalized dose was described by AUCINF/D and was the basis for comparison between H-25357 and positive controls. The AUCINF/D for the fluorine component of H-25357 was 8.61×10^2 as compared to AUCINF/D

values of 5.22×10^5 and 8.15×10^4 for H-24019 and H-24020, respectively. There was no detectable fluorine in the blood on days 52 and 94 in rats dosed with the test substance.

Levels of total fluorine in livers from rats dosed with the test substance, H-25357, were lower than the levels in livers from rats dosed with the positive control materials. The total fluorine concentration in the liver from rats dosed with H-25357 was 114.94 μM equivalents at day 10 and 6.96 μM equivalents at day 94. For the positive control H-24019, the liver concentrations were approximately 42x higher (day 10) and approximately 186x higher (end of study) than H-25357. For H-24020, the liver concentrations were approximately 8x higher (end of dosing) and 2x higher (end of study) than H-25357.

Levels of total fluorine in fat from rats dosed with the test substance were lower on day 10 but similar on day 94 to the levels in fat from rats dosed with the positive control material H-24019. The levels in fat from rats dosed with the test substance were higher than levels in fat from rats dosed with the positive control material H-24020. The fluorine concentration in the fat from rats dosed with the test substance was 107.79 μM equivalents on day 10 and 13.59 μM equivalents on day 94. The fluorine concentration of one of the positive control materials, H-24019, was approximately 2x higher than H-25357 on day 10. The fluorine concentration of the test substance, H-25357, was approximately 2x higher than the fluorine concentration of the other positive control material, H-24020. By day 94, the fluorine concentration of H-24019 was similar to the fluorine concentration in rats treated with H-25357. There was no detectable fluorine by day 94 in the fat from rats dosed with H-24020.

The μM equivalents in the liver and fat were higher than levels in the blood.

CONCLUSIONS

Rats dosed for 10 consecutive days with 1000 mg/kg H-25357 exhibited no mortality, no test substance-related clinical signs, and no body weight effects. Liver weights were affected in rats dosed with the test substance. A steady-state for fluorine in the blood appeared to be achieved during the 10-day dosing period with the test substance. Dose-adjusted areas under the curve (AUCINF/D) for positive controls, H-24019 and H-24020, were approximately 600x and 95x the AUCINF/D for the test substance.

Under the conditions of this study, there was limited absorption and no retention of fluorine in the blood following dosing with H-25357. Administration of the test substance, H-25357, to male rats for 10 consecutive days resulted in some absorption and retention of fluorine in the liver and fat. However, levels in blood and liver in rats dosed with H-25357 were generally lower than the fluorine levels in rats dosed with the positive control materials, H-24019 and H-24020. Levels in fat in rats dosed with H-25357 were lower than at day 10 but similar to the levels at day 94 in rats dosed with the positive control H-24019. Levels in fat from rats dosed with the test substance were higher than levels in fat from rats dosed with the positive control H-24020.

Company Sanitized. Does not contain TSCA CBI

RECORDS AND SAMPLE STORAGE

Specimens (if applicable), raw data, and the final report will be retained at Haskell Laboratory, Newark, Delaware, or at Iron Mountain Records Management, Wilmington, Delaware.

Company Sanitized. Does not contain TSCA CBI

TABLES

Company Sanitized. Does not contain TSCA CBI

TABLE 1
MEAN BODY WEIGHTS

DAYS ON TEST	MEAN BODY WEIGHTS (g)			
	Negative Control	Positive Controls		Test Substance
	Deionized Water	H-24019	H-24020	H-25357
1	189.6	184.4	184.1	192.8
2	195.5	189.2	187.8	199.1
3	204.6	199.5	197.8	208.0
4	211.7	206.4	204.8	217.3
5	222.1	216.2	212.5	230.1
6	225.0	222.0	216.0	236.6
7	235.2	229.4	223.6	245.0
8	242.3	233.7	226.9	253.0
9	248.3	240.4	234.2	260.1
10	257.0	246.5	243.0	266.8
17	293.3	290.1	297.4	311.4
24	325.5	313.3	338.6	345.8
31	359.3	348.4	381.9	377.1
38	380.9	370.8	404.9	406.2
45	407.4	403.2	434.4	442.2
52	420.5	422.8	460.6	468.1
59	436.4	439.6	483.1	486.7
66	-	-	-	-
67	452.8	455.6	502.7	503.9
73	472.6	480.1	525.6	520.7
80	489.6	496.5	542.1	536.8
87	497.7	512.2	546.2	539.2
94	511.7	524.6	570.5	551.9

- Indicates the animals were not weighed

Company Sanitized. Does not contain TSCA CBI

TABLE 2
MEAN BODY WEIGHT GAINS
DOSING

DAYS ON TEST	MEAN BODY WEIGHT GAINS (g)			
	Negative Control	Positive Controls		Test Substance
	Deionized Water	H-24019	H-24020	H-25357
1-5	32.5	31.8	28.4	37.3
5-10	34.9	30.3	30.5	36.7
1-10	67.4	62.1	58.9	74.0

RECOVERY

DAYS ON TEST	MEAN BODY WEIGHT GAINS (g)			
	Negative Control	Positive Controls		Test Substance
	Deionized Water	H-24019	H-24020	H-25357
10-17	36.3	43.6	54.4	44.6
17-24	32.2	23.2	41.2	34.4
24-52	95.0	109.5	122.0	122.3
52-94	91.2	101.8	109.9	83.8
10-94	254.7	278.1	327.5	285.1

Company Sanitized. Does not contain TSCA CBI

TABLE 3

MEAN BODY AND LIVER WEIGHTS

NEGATIVE CONTROL - DEIONIZED WATER			
DAYS ON TEST	WEIGHT (g)		Mean Relative Liver Weight (Liver/Body Weight)
	Absolute		
	Body Weight	Liver Weight	
10	258.8	10.814	0.042
94	511.7	17.868	0.035
POSITIVE CONTROL - H-24019			
DAYS ON TEST	WEIGHT (g)		Mean Relative Liver Weight (Liver/Body Weight)
	Absolute		
	Body Weight	Liver Weight	
10	243.9	14.205	0.058
94	524.6	19.296	0.037
POSITIVE CONTROL - H-24020			
DAYS ON TEST	WEIGHT (g)		Mean Relative Liver Weight (Liver/Body Weight)
	Absolute		
	Body Weight	Liver Weight	
10	243.1	19.174	0.079
94	570.5	19.590	0.034
TEST SUBSTANCE - H-25357			
DAYS ON TEST	WEIGHT (g)		Mean Relative Liver Weight (Liver/Body Weight)
	Absolute		
	Body Weight	Liver Weight	
10	266.2	13.851	0.052
94	551.9	19.681	0.036

Company Sanitized. Does not contain TSCA CBI

TABLE 4
MEAN BLOOD FLUORINE LEVELS

DAYS ON TEST	MEAN FLUORINE LEVELS (ppm)			
	Negative Control	Positive Controls		Test Substance
	Deionized Water	H-24019	H-24020	H-25357
1	0.60 ^a	2.60 (0.1) ^b	9.40 (2.4)	1.11 (0.1)
5	- ^c	31.32 (1.1)	74.92 (7.0)	3.19 (0.2)
10	1.10 ^a	68.00 (3.5)	61.76 (5.5)	2.87 (0.3)
13	- ^c	53.98 (1.2)	29.52 (4.9)	2.27 (0.3)
24	0.5 ^a	39.62 (3.4)	11.18 (2.9)	2.28 (0.6)
52	- ^c	23.56 (2.1)	2.26 (1.1)	- ^c - ^c
94	- ^c	12.60 (1.2)	0.85 (0.1) ^d	- ^c - ^c

a One of 5 values. Four of the values were below the limit of quantification (LOQ) or non-detectable.

b Standard deviation (S.D.) is in parentheses.

c All values were below the LOQ or non-detectable.

d Mean of 2 of the 5 values. Three of the values were below the LOQ.

TABLE 5
MEAN BLOOD FLUORINE CONCENTRATION NORMALIZED TO DOSE

DAYS ON TEST	MEAN FLUORINE CONCENTRATION (µM F Equivalents)		
	Positive Controls		Test Substance
	H-24019	H-24020	H-25357
1	36.92 (1.1) ^a	66.67 (17.5)	4.79 (0.6)
5	478.77 (17.6)	541.45 (50.4)	15.74 (0.9)
10	1043.08 (54.6)	446.09 (39.7)	14.07 (1.4)
13	827.38 (19.0)	212.46 (35.6)	10.87 (1.4)
24	606.46 (53.1)	79.57 (20.8)	10.97 (3.2)
52	359.38 (32.7)	14.93 (7.7)	- ^c - ^c
94	190.77 (19.2)	4.71 (0.5) ^b	- ^c - ^c

a Standard deviation (S.D.) is in parentheses.

b Mean of 2 of the 5 values. Three of the values were below the limit of quantification (LOQ).

c All values were below the LOQ.

Company Sanitized. Does not contain TSCA CBI

TABLE 6
MEAN LIVER FLUORINE LEVELS

DAYS ON TEST	MEAN FLUORINE LEVELS (ppm)			
	Negative Control	Positive Controls		Test Substance
	Deionized Water	H-24019	H-24020	H-25357
10	0.90 (0.2) ^a	312.34 (19.7)	119.80 (3.5)	22.04 (2.8)
94	0.78 (0.0)	84.24 (7.4)	2.56 (1.3)	1.52 (0.2)

a Standard deviation (S.D.) is in parentheses.

TABLE 7
MEAN LIVER FLUORINE CONCENTRATION NORMALIZED TO DOSE

DAYS ON TEST	MEAN FLUORINE CONCENTRATION (µM F Equivalents)		
	Positive Controls		Test Substance
	H-24019	H-24020	H-25357
10	4802.15 (303.8) ^a	866.67 (25.5)	114.94 (14.9)
94	1292.92 (114.1)	17.10 (9.8)	6.96 (1.1)

a Standard deviation (S.D.) is in parentheses.

Company Sanitized. Does not contain TSCA CBI

TABLE 8
MEAN FAT FLUORINE LEVELS

DAYS ON TEST	MEAN FLUORINE LEVELS (ppm)			
	Negative Control	Positive Controls		Test Substance
	Deionized Water	H-24019	H-24020	H-25357
10	- ^a	12.84 (1.7) ^b	8.10 (1.1)	21.06 (3.8)
94	- ^a	1.20 (0.3)	- ^a	2.78 (0.8)

a All values were below the limit of quantification (LOQ) or non-detectable.

b Standard deviation (S.D.) is in parentheses.

TABLE 9
MEAN FAT FLUORINE CONCENTRATION NORMALIZED TO DOSE

DAYS ON TEST	MEAN FLUORINE CONCENTRATION (µM F Equivalents)		
	Positive Controls		Test Substance
	H-24019	H-24020	H-25357
10	194.46 (26.8) ^a	57.25 (7.8)	109.79 (19.8)
94	15.38 (4.1)	- ^b	13.59 (4.2)

a Standard deviation (S.D.) is in parentheses.

b All values were below the limit of quantification (LOQ) or non-detectable.

Company Sanitized. Does not contain TSCA CB

FIGURES

Company Sanitized. Does not contain TSCA CBI

FIGURE 1
MEAN BODY WEIGHTS




FIGURE 2

COMPARISON OF MEAN RELATIVE LIVER WEIGHTS:
TEST SUBSTANCE AND NEGATIVE CONTROL




FIGURE 3

COMPARISON OF MEAN RELATIVE LIVER WEIGHTS:
TEST SUBSTANCE AND POSITIVE CONTROLS





FIGURE 4


MICROMOLAR EQUIVALENTS IN RAT BLOOD

A. Normalized Rat Blood H-24019 μM Equivalents Resulting from a 10-Day Oral Gavage




Micromolar (μM) equivalents of H-24019 (positive control) in rat blood resulting from a 10-day oral gavage exposure. Values are means and error bars are standard deviation.

B. Normalized Rat Blood H-24020 μM Equivalents Resulting from a 10-Day Oral Gavage



Micromolar (μM) equivalents of H-24020 (positive control) in rat blood resulting from a 10-day oral gavage exposure. Values are means and error bars are standard deviation.

C. Normalized Rat Blood H-25357 μM Equivalents Resulting from a 10-Day Oral Gavage



Micromolar (μM) equivalents of H-25357 (test substance) in rat blood resulting from a 10-day oral gavage exposure. Values are means and error bars are standard deviation.

Company Sanitized. Does not contain TSCA CBI

FIGURE 5
NORMALIZED H-25357 AND POSITIVE CONTROL BLOOD AUCINF/D
RESULTING FROM A 10-DAY ORAL GAVAGE




FIGURE 6

MEAN LIVER FLUORINE CONCENTRATION NORMALIZED TO DOSE




FIGURE 7

COMPARISON OF RELATIVE LIVER WEIGHT AND MEAN LIVER FLUORINE CONCENTRATION
FOR H-25357 AND NEGATIVE CONTROL




FIGURE 8

MEAN FAT FLUORINE CONCENTRATION NORMALIZED TO DOSE





FIGURE 9

COMPARISON OF MEAN BLOOD, MEAN LIVER, AND MEAN FAT FLUORINE
CONCENTRATION NORMALIZED TO DOSE



APPENDICES

Company Sanitized. Does not contain TSCA CBI

APPENDIX A

Individual Body Weights

Company Sanitized. Does not contain TSCA CBI

INDIVIDUAL BODY WEIGHTS

EXPLANATORY NOTES

ABBREVIATIONS:

SD - sacrificed by design

Company Sanitized. Does not contain toxic oil

DEIONIZED WATER (NEGATIVE CONTROL)
INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS

GROUP I

ANIMAL NUMBER	TEST DAY								
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9
646932	197.1	202.1	212.9	221.5	233.6	234.1	242.4	251.1	256.1
646933	191.9	195.4	205.0	213.2	226.5	219.3	232.9	239.5	246.4
646934	182.6	188.9	195.4	207.0	213.9	215.9	224.2	230.9	238.1
646935	203.0	208.9	218.0	228.1	239.7	243.0	257.2	265.7	270.5
646936	196.8	201.4	208.6	204.0	216.7	218.6	229.9	234.9	240.3

TEST DAY

ANIMAL
NUMBER Day 10

646932	264.7	SD test day 10
646933	254.4	SD test day 10
646934	248.6	SD test day 10
646935	278.0	SD test day 10
646936	248.1	SD test day 10

DEIONIZED WATER (NEGATIVE CONTROL)

INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS

GROUP III

ANIMAL NUMBER	TEST DAY								
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9
646937	184.5	186.8	199.0	205.9	213.6	221.0	229.6	238.7	241.4
646938	163.7	173.8	180.9	189.3	200.6	204.1	215.9	221.8	228.3
646939	193.3	204.2	214.6	221.1	234.4	240.7	248.9	259.2	267.3
646940	191.5	197.1	203.8	209.8	218.5	222.1	229.3	232.0	237.5
646941	191.6	195.9	207.9	216.8	223.1	231.2	241.3	249.1	257.0

ANIMAL NUMBER	TEST DAY								
	Day 10	Day 17	Day 24	Day 31	Day 38	Day 45	Day 52	Day 59	Day 67
646937	249.8	282.6	322.3	366.1	395.0	425.0	443.9	461.7	478.7
646938	237.2	270.4	296.5	325.8	342.9	367.5	373.7	378.7	401.3
646939	277.9	329.7	372.8	415.2	443.2	475.2	484.1	505.7	516.4
646940	244.5	271.5	291.3	317.9	332.8	356.3	367.0	380.3	392.5
646941	266.3	312.4	344.8	371.6	390.7	412.8	433.6	455.8	475.3

ANIMAL NUMBER	TEST DAY			
	Day 73	Day 80	Day 87	Day 94
646937	504.3	520.5	533.7	545.7 SD test day 94
646938	417.4	431.0	432.1	450.6 SD test day 94
646939	540.1	568.9	578.1	586.9 SD test day 94
646940	407.3	424.0	430.8	449.4 SD test day 94
646941	493.7	503.5	513.8	525.8 SD test day 94

H-25357: Biopersistence Screening
10-Dose Oral Gavage Study in Rats

DuPont-11557

H-24019 (POSITIVE CONTROL)

INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS

GROUP I

ANIMAL NUMBER	TEST DAY								
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9
646910	184.3	185.3	197.3	204.8	212.7	216.3	226.4	232.3	237.5
646911	184.4	187.1	195.7	202.0	211.7	217.2	225.2	225.6	231.9
646912	180.5	185.9	195.9	202.5	211.9	217.7	227.2	232.4	238.5
646913	186.4	189.7	198.1	205.7	221.8	225.0	228.6	238.4	245.8
646914	185.5	189.6	198.8	203.8	215.4	222.7	226.7	231.5	238.8

TEST DAY

ANIMAL
NUMBER

Day 10

646910	241.1	SD test day 10
646911	236.6	SD test day 10
646912	241.9	SD test day 10
646913	257.0	SD test day 10
646914	243.0	SD test day 10

DuPont-11557

INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS

ANIMAL NUMBER	TEST DAY								
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9
646915	182.7	188.3	200.1	206.3	211.1	220.6	225.8	231.1	236.8
646916	185.0	192.7	205.5	211.6	220.0	226.9	239.5	240.1	249.3
646917	187.8	194.3	205.8	210.4	221.8	227.5	233.9	244.3	249.3
646918	175.5	181.9	189.8	197.6	207.0	212.4	220.2	224.1	228.2
646919	192.0	196.9	207.9	218.9	228.3	234.0	240.8	245.8	252.9

ANIMAL NUMBER	TEST DAY								
	Day 10	Day 17	Day 24	Day 31	Day 38	Day 45	Day 52	Day 59	Day 67
646915	240.4	283.4	302.9	326.7	337.9	371.1	399.7	412.5	433.1
646916	257.0	310.0	334.4	383.2	411.9	450.3	469.8	494.8	511.8
646917	250.2	280.3	308.2	339.7	362.8	387.9	409.0	420.0	441.5
646918	237.1	270.6	292.7	323.2	350.8	379.4	396.7	418.8	433.8
646919	260.2	306.1	328.5	369.2	390.4	427.3	439.0	451.7	457.6

ANIMAL NUMBER	Day 73	Day 80	Day 87	Day 94	TEST DAY
646915	461.2	475.0	498.1	513.3	SD test day 94
646916	544.2	565.5	578.5	590.9	SD test day 94
646917	457.5	464.7	479.5	495.7	SD test day 94
646918	448.1	472.5	480.8	500.3	SD test day 94
646919	489.5	504.8	524.2	522.9	SD test day 94

H-24020 (POSITIVE CONTROL)

INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS

GROUP I

ANIMAL NUMBER	TEST DAY								
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9
646921	204.5	204.9	215.7	222.2	233.3	238.8	244.3	244.9	252.2
646922	178.3	180.9	188.9	197.4	197.7	202.4	202.4	204.0	207.7
646923	185.9	185.1	196.0	202.3	203.5	204.9	219.1	224.9	231.7
646924	188.7	194.6	209.5	212.6	230.4	225.9	236.2	236.5	250.9
646925	172.2	176.0	183.9	193.4	202.7	202.7	215.1	221.5	228.7

TEST DAY

ANIMAL
NUMBER Day 10

646921	262.6	SD test day 10
646922	218.6	SD test day 10
646923	240.6	SD test day 10
646924	259.1	SD test day 10
646925	234.8	SD test day 10

DuPont-11557

INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS

ANIMAL NUMBER	TEST DAY								
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9
646926	182.0	187.8	197.0	203.6	206.0	213.2	222.9	229.9	239.7
646927	172.2	178.8	191.1	195.1	206.6	213.2	218.2	228.7	233.1
646928	190.4	195.3	204.5	212.3	222.1	230.1	236.1	235.8	243.4
646929	178.6	182.5	190.7	198.3	203.5	204.2	214.6	210.3	219.2
646930	187.9	191.6	201.0	210.4	219.6	224.4	226.7	232.6	235.3

ANIMAL NUMBER	TEST DAY								
	Day 10	Day 17	Day 24	Day 31	Day 38	Day 45	Day 52	Day 59	Day 67
646926	250.8	297.2	349.3	383.8	412.1	432.1	467.8	493.2	509.5
646927	243.3	306.2	355.1	404.0	424.8	463.2	484.0	511.7	527.2
646928	254.1	310.6	349.4	392.8	422.4	443.5	464.8	492.2	518.6
646929	225.5	280.9	323.2	376.0	396.8	426.4	450.2	463.8	484.2
646930	240.3	292.3	316.2	352.7	368.4	406.8	436.0	454.7	474.2

ANIMAL NUMBER	TEST DAY		
	Day 73	Day 80	Day 94
646926	535.3	551.9	580.6
646927	551.2	574.5	602.5
646928	540.3	557.0	581.9
646929	502.6	509.6	544.0
646930	498.5	517.6	543.4

H-25357: Biopersistence Screening
10-Dose Oral Gavage Study in Rats

DuPont-11557

H-25357 (TEST SUBSTANCE)

INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS

GROUP I

ANIMAL NUMBER	TEST DAY								
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9
665500	203.3	205.2	212.7	223.3	234.2	242.8	250.4	256.5	265.0
665501	194.1	197.0	210.3	219.0	235.2	242.0	244.5	256.4	265.4
665502	196.4	202.2	212.6	221.0	236.3	241.7	251.1	259.3	268.9
665503	180.3	189.8	198.0	206.0	219.3	223.2	238.1	247.2	249.1
665505	195.0	201.1	209.8	218.6	230.9	230.8	238.9	245.0	252.0

TEST DAY

ANIMAL
NUMBER

Day 10

665500	273.5	SD test day 10
665501	266.1	SD test day 10
665502	275.7	SD test day 10
665503	258.5	SD test day 10
665505	257.1	SD test day 10

H-25357 (TEST SUBSTANCE)

INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS

GROUP III

ANIMAL NUMBER	TEST DAY					TEST DAY				
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9	
665506	191.0	201.7	208.9	213.8	225.9	238.8	242.3	253.7	261.3	
665507	190.7	199.1	205.0	216.1	224.4	236.2	245.0	247.4	251.8	
665508	187.3	194.3	199.1	211.7	220.7	227.7	234.7	242.3	248.2	
665509	196.3	199.4	210.1	220.4	234.3	238.7	249.3	255.1	261.2	
665510	193.7	201.5	213.1	223.0	239.9	243.7	255.6	266.7	277.7	
ANIMAL NUMBER	TEST DAY					TEST DAY				
	Day 10	Day 17	Day 24	Day 31	Day 38	Day 45	Day 52	Day 59	Day 67	
665506	273.5	314.5	342.9	377.0	410.8	455.5	487.4	501.0	515.4	
665507	263.9	305.7	337.8	366.6	388.2	414.8	437.5	450.3	462.0	
665508	251.5	285.8	314.0	332.3	351.3	374.3	395.9	416.9	431.7	
665509	265.4	303.4	334.6	363.0	397.0	432.1	454.6	477.1	504.7	
665510	283.0	347.4	399.7	446.4	483.7	534.3	564.9	588.2	605.6	
ANIMAL NUMBER	TEST DAY					TEST DAY				
	Day 73	Day 80	Day 87	Day 94						
665506	532.2	555.6	558.9	576.0	SD test day 94					
665507	478.2	488.1	488.9	495.6	SD test day 94					
665508	446.6	463.3	470.5	483.1	SD test day 94					
665509	519.0	532.6	530.2	539.0	SD test day 94					
665510	627.7	644.4	647.6	665.7	SD test day 94					

APPENDIX B

Individual Clinical Observations

Company Sanitized. Does not contain TSCA CBI

DEIONIZED WATER (NEGATIVE CONTROL)
INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

Animal	Observation	GROUP	Days
646932	General observation, No Abnormality Detected		1
	Eye Observations, Exophthalmus, Left		2-9
	Eye Observations, Bled via Orbital for Clin Path, Left		1,5
	Discharge, Eye left, Black		10
	Sacrificed by design		10
646933	General observation, No Abnormality Detected		1-5
	Eye Observations, Bled via Orbital for Clin Path, Left		1,5
	Eye Observations, Dark, Left		6-10
	Discharge, Eye left, Black		6-7
	Swollen Observations, Mouth		10
	Sacrificed by design		10
646934	General observation, No Abnormality Detected		1-5,10
	Eye Observations, Bled via Orbital for Clin Path, Left		1,5
	Discharge, Eye left, Black		6-9
	Sacrificed by design		10

DEIONIZED WATER (NEGATIVE CONTROL)		
INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS		
GROUP I (Continued)		
Animal	Observation	Days
646935	General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Left	1,5
	Sacrificed by design	10
646936	General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Left	1,5
	Sacrificed by design	10

DEIONIZED WATER (NEGATIVE CONTROL)
INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP III

Animal	Observation	Days
646937	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Left	13
	Eye Observations, Bled via Orbital for Clin Path, Right	24, 52
	Sacrificed by design	94
646938	General observation, No Abnormality Detected	1-10, 17-45
	Eye Observations, Enophthalmus, Right	80-94
	Eye Observations, Exophthalmus, Right	52-73
	Eye Observations, Bled via Orbital for Clin Path, Bilateral	13, 52
	Eye Observations, Bled via Orbital for Clin Path, Right	24
	Eye Observations, Corneal Opacity, Right	80-94
	Discharge, Eye right, Black	59
	Sacrificed by design	94
646939	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Left	13
	Eye Observations, Bled via Orbital for Clin Path, Right	24, 52
	Sacrificed by design	94

DEIONIZED WATER (NEGATIVE CONTROL)
INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP III (Continued)

Animal	Observation	Days
646940	General observation, No Abnormality Detected	1-10, 17-80, 94
	Eye Observations, Bled via Orbital for Clin Path, Left	13
	Eye Observations, Bled via Orbital for Clin Path, Right	24, 52
	Discharge, Nose, Black	87
	Sacrificed by design	94
646941	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Bilateral	52
	Eye Observations, Bled via Orbital for Clin Path, Left	13
	Eye Observations, Bled via Orbital for Clin Path, Right	24
	Sacrificed by design	94

H-24019 (POSITIVE CONTROL)

INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP I

Animal	Observation	Days
646910	General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Left	1,5
	Sacrificed by design	10
646911	General observation, No Abnormality Detected	1,10
	Eye Observations, Bled via Orbital for Clin Path, Left	1,5
	Eye Observations, Dark, Left	2-9
	Sacrificed by design	10
646912	General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Left	1
	Eye Observations, Bled via Orbital for Clin Path, Right	5
	Sacrificed by design	10
646913	General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Left	1,5
	Sacrificed by design	10
646914	General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Left	1,5
	Sacrificed by design	10

H-24019 (POSITIVE CONTROL)

INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP III

Animal	Observation	Days
646915	General observation, No Abnormality Detected	1, 17-38, 73
	Eye Observations, Bled via Orbital for Clin Path, Left	13, 24, 52
	Discharge, Eye right, Red	2-10
	Hair Loss, Forelimb, Right	80
	Hair Loss, Forepaw, Right	45-67, 87-94
	Sacrificed by design	94
646916	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Bilateral	24
	Eye Observations, Bled via Orbital for Clin Path, Left	13
	Eye Observations, Bled via Orbital for Clin Path, Right	52
	Sacrificed by design	94
646917	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Left	13, 24
	Eye Observations, Bled via Orbital for Clin Path, Right	52
	Sacrificed by design	94

H-24019 (POSITIVE CONTROL)

INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP III (Continued)

Animal	Observation	Days
646918	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Left	13, 24
	Eye Observations, Bled via Orbital for Clin Path, Right	52
	Sacrificed by design	94
646919	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Left	13, 24
	Eye Observations, Bled via Orbital for Clin Path, Right	52
	Sacrificed by design	94

H-24020 (POSITIVE CONTROL)

INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP I

Animal	Observation	Days
646921	General observation, No Abnormality Detected	1, 5-10
	Eye Observations, Bled via Orbital for Clin Path, Left	1, 5
	Eye Observations, Dark, Left	2-4
	Sacrificed by design	10
646922	General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Left	1
	Eye Observations, Bled via Orbital for Clin Path, Right	5
	Sacrificed by design	10
646923	General observation, No Abnormality Detected	1, 7-10
	Eye Observations, Exophthalmus, Left	4-6
	Eye Observations, Bled via Orbital for Clin Path, Left	1
	Eye Observations, Bled via Orbital for Clin Path, Right	5
	Eye Observations, Dark, Left	2-6
	Sacrificed by design	10

H-24020 (POSITIVE CONTROL)
INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP I (Continued)

Animal	Observation	Days
646924	General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Left	1
	Eye Observations, Bled via Orbital for Clin Path, Right	5
	Sacrificed by design	10
646925	General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Left	1
	Eye Observations, Bled via Orbital for Clin Path, Right	5
	Sacrificed by design	10

H-24020 (POSITIVE CONTROL)

INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP III

Animal	Observation	Days
646926	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Bilateral	52
	Eye Observations, Bled via Orbital for Clin Path, Left	13, 24
	Sacrificed by design	94
646927	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Bilateral	52
	Eye Observations, Bled via Orbital for Clin Path, Left	13, 24
	Sacrificed by design	94
646928	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Left	13, 24, 52
	Sacrificed by design	94

H-24020 (POSITIVE CONTROL)

INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP III (Continued)

Animal	Observation	Days
646929	General observation, No Abnormality Detected	1-10, 17-31
	Eye Observations, Bled via Orbital for Clin Path, Left	13, 24
	Eye Observations, Bled via Orbital for Clin Path, Right	52
	Hair Loss, Forelimb, Bilateral	52-73
	Hair Loss, Neck, Left	73
	Hair Loss, Neck, Ventral	38-67, 80-94
	Wound, Superficial, Face	59
	Sacrificed by design	94
646930	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Left	13, 24
	Eye Observations, Bled via Orbital for Clin Path, Right	52
	Sacrificed by design	94

H-25357 (TEST SUBSTANCE)

INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP I

Animal	Observation	Days
M	665500 General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Right	1,5
	Sacrificed by design	10
M	665501 Eye Observations, Bled via Orbital for Clin Path, Right	1,5
	Hair Loss, Ventral body, Ventral	1-10
	Sacrificed by design	10
M	665502 General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Right	1,5
	Sacrificed by design	10
M	665503 General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Right	1,5
	Sacrificed by design	10
M	665505 General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Right	1,5
	Sacrificed by design	10

H-25357 (TEST SUBSTANCE)

INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP III

Animal	Observation	Days
665506	General observation, No Abnormality Detected	1-94
	Eye Observations, Bled via Orbital for Clin Path, Right	24, 52
	Sacrificed by design	94
665507	General observation, No Abnormality Detected	1-94
	Eye Observations, Bled via Orbital for Clin Path, Right	24, 52
	Sacrificed by design	94
665508	General observation, No Abnormality Detected	1-94
	Eye Observations, Bled via Orbital for Clin Path, Right	24, 52
	Sacrificed by design	94
665509	General observation, No Abnormality Detected	1-24, 38-94
	Eye Observations, Bled via Orbital for Clin Path, Right	24, 52
	Hair Loss, Forepaw, Bilateral	31
	Sacrificed by design	94
665510	General observation, No Abnormality Detected	1-94
	Eye Observations, Bled via Orbital for Clin Path, Right	24-52
	Sacrificed by design	94

APPENDIX C

Terms and Calculations Factors Influencing Interpretation of Kinetic Analysis

Company Sanitized. Does not contain TSCA CEI

TERMS AND CALCULATIONS

Terms:

Active	Fluorine containing compound
% Active	The % of formulation that is made up of fluorine containing components
Mol Wt Active	The molecular weight of the fluorine containing components (g/mole)
Formulation Dose	The mg of formulation given per kg of animal body weight
% F in Active	The % fluorine in the fluorine containing components of the formulation (weight basis)
Mol Wt F	The molecular weight of fluorine g/mol

Compound Calculations:

Dose Active (mg/kg)	The mg of fluorine containing compound administered per kg of animal body weight. $= (\% \text{ active}/100) \times \text{Formulation Dose}$
Dose Active (mmole/kg)	The mmole of fluorine containing compound administered per kg of animal body weight $= \text{dose [mg/kg]} / \text{Mol Wt Active [mg/mmol]}$
Dose F (mg/kg)	The mg Fluorine administered per kg of animal body weight $= (\% \text{ F in active}/100) \times \text{Dose Active [mg/kg]}$
Dose F (mmol/kg)	The mmole of fluorine administered per kg of animal body weight $= \text{Dose F [mg/kg]} / \text{Mol Wt F [mg/mmol]}$
Molar Ratio (Active/F)	The moles of fluorine containing compound per mole of fluorine $= \text{Dose Active [mmol/kg]} / \text{Dose F [mmol/kg]}$
Formulation Dose Normalization Factor	The formulation dose that would be required to administer the amount of active needed to achieve the normalized dose $= (\text{Normalized dose of Active [mmol/kg]} / \text{Dose Active [mmol/kg]}) \times \text{Formulation Dose}$

Company Sanitized. Does not contain TSCA CBI

TERMS AND CALCULATIONS

Individual Animal Measurement:

ppm F The ppm fluoride measured

Individual Animal Calculations:

ppm F minus
Bkg 0.2 ppm The ppm fluoride measured minus the background fluoride measured
in control animal. In this case the value was established at 0.2 ppm.

ppm F
normalized to
0.1 mmol/kg Dose The ppm fluoride minus background that would be expected if the
active dose was 0.1 mmol/kg instead of the actual active dose. This
assumes linearity between administered dose and blood fluorine
levels, but is needed because different doses of active were used in the
study.
= (0.1 [mmol/kg] / Active dose [mmol/kg]) x (ppm F in blood
minus background)

μmolar equivalents of
active The μmolar [μmol/L] concentration of fluorine containing compound
based on the ppm fluorine normalized to 0.1 mmol/kg active dose.
This assumes that all fluorine is derived from the fluorine-containing
component in the formulation. Note: 1 ppm – 1 mg/L
= (Normalized ppm [mg/L] fluorine / Mol Wt F [mg/mmol]) x
molar ratio active/F [mmol active/mmol F] x 1000 μmol/mmol

Company Sanitized. Does not contain TSCA CBI

FACTORS INFLUENCING INTERPRETATION OF KINETIC ANALYSIS

Considerations:

- The data used for kinetic analysis was from a limited screen and extrapolation should be done cautiously.
- Sample size is low
- Analytical data used without validation
- Steady-state not reached
- Terminal phase may not be reached
- Some compounds are mixtures of fluorinated compounds
- Different active and formulation doses were used
- Different vehicles were used to deliver formulations
- Each compound may have very different potency for producing toxicity

Assumptions: (May or may not be justified in all cases)

- Fluorine concentrations are linear with respect to dose
- Analytical method is appropriate for all types of compounds
- Elimination kinetics can be determined based on total fluorine rather than on concentrations of individual components
- Background Fluorine is 0.2 ppm
- % F data is the % Fluorine of the active (Fluorine containing component(s) in the formulation)
- Molecular weight is the molecular weight of the active component in the formulation

Company Sanitized. Does not contain TSCA CBI

APPENDIX D

Individual Fluorine Levels in Blood

Company Sanitized. Does not contain TSCA CBI

Data for H-24019

Given:

Mol Wt. Active (g/mole):	497	% F in Active:	65
Formulation Dose (mg/kg):	10	Mol Wt. F (g/mol):	19
% Active (F Containing) in Formulation:	100		

Calculated Values:

Dose Active (mg/kg):	10	Molar Ratio (Active/F):	0.059
Dose Active (mmole/kg):	0.020	Dose F (mg/kg):	6.5
Dose F (mmol/kg):	0.342		

Rat Number	Test Day Sample	ppm F in Blood	ppm F in Blood Minus Bkg 0.2 ppm	ppm F in Blood Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Blood
Group I					
646910	1	2.6	2.4	11.93	36.92
646911	1	2.7	2.5	12.43	38.46
646912	1	2.5	2.3	11.43	35.38
646913	1	2.6	2.4	11.93	36.92
646914	1	2.6	2.4	11.93	36.92
Group I					
646910	5	30.1	29.9	148.60	460.00
646911	5	30.3	30.1	149.60	463.08
646912	5	31.3	31.1	154.57	478.46
646913	5	32.2	32.0	159.04	492.31
646914	5	32.7	32.5	161.53	500.00
Group I					
646910	10	71.5	71.3	354.36	1096.92
646911	10	70.5	70.3	349.39	1081.54
646912	10	66.9	66.7	331.50	1026.15
646913	10	62.5	62.3	309.63	958.46
646914	10	68.6	68.4	339.95	1052.31

Company Sanitized. Does not contain TSCA CBI

Rat Number	Test Day Sample	ppm F in Blood	ppm F in Blood Minus Bkg 0.2 ppm	ppm F in Blood Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Blood
Group III					
646915	13	55.0	54.8	272.36	843.08
646916	13	55.3	55.1	273.85	847.69
646917	13	52.2	52.0	258.44	800.00
646918	13	53.8	53.6	266.39	824.62
646919	13	53.6	53.4	265.40	821.54
Group III					
646915	24	38.9	38.7	192.34	595.38
646916	24	43.8	43.6	216.69	670.77
646917	24	37.6	37.4	185.88	575.38
646918	24	35.4	35.2	174.94	541.54
646919	24	42.4	42.2	209.73	649.23
Group III					
646915	52	23.2	23.0	114.31	353.85
646916	52	20.3	20.1	99.90	309.23
646917	52	25.9	25.7	127.73	395.38
646918	52	24.9	24.7	122.76	380.00
646919	52	23.5	23.3	115.80	358.46
Group III					
646915	94	13.3	13.1	65.11	201.54
646916	94	11.7	11.5	57.16	176.92
646917	94	12.9	12.7	63.12	195.38
646918	94	11.0	10.8	53.68	166.15
646919	94	14.1	13.9	69.08	213.85

Company Sanitized. Does not contain TSCA CBI

Data for H-24020

Given:

Mol Wt. Active (g/mole):	426	% F in Active:	69
Formulation Dose (mg/kg):	20	Mol Wt. F (g/mol):	19
% Active (F Containing) in Formulation:	100		

Calculated Values:

Dose Active (mg/kg):	20	Molar Ratio (Active/F):	0.065
Dose Active (mmole/kg):	0.047	Dose F (mg/kg):	13.8
Dose F (mmol/kg):	0.726		

Rat Number	Test Day Sample	ppm F in Blood	ppm F in Blood Minus Bkg 0.2 ppm	ppm F in Blood Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Blood
Group I					
646921	1	10.6	10.4	22.15	75.36
646922	1	10.7	10.5	22.37	76.09
646923	1	9.2	9.0	19.17	65.22
646924	1	5.3	5.1	10.86	36.96
646925	1	11.2	11.0	23.43	79.71
Group I					
646921	5	78.7	78.5	167.21	568.84
646922	5	83.2	83.0	176.79	601.45
646923	5	77.0	76.8	163.58	556.52
646924	5	66.1	65.9	140.37	477.54
646925	5	69.6	69.4	147.82	502.90
Group I					
646921	10	63.0	62.8	133.76	455.07
646922	10	69.1	68.9	146.76	499.28
646923	10	60.3	60.1	128.01	435.51
646924	10	62.5	62.3	132.70	451.45
646925	10	53.9	53.7	114.38	389.13

Company Sanitized. Does not contain TSCA CBI

Rat Number	Test Day Sample	ppm F in Blood	ppm F in Blood Minus Bkg 0.2 ppm	ppm F in Blood Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Blood
Group III					
646926	13	34.8	34.6	73.70	250.72
646927	13	30.0	29.8	63.47	215.94
646928	13	23.7	23.5	50.06	170.29
646929	13	33.7	33.5	71.36	242.75
646930	13	25.4	25.2	53.68	182.61
Group III					
646926	24	11.9	11.7	24.92	84.78
646927	24	10.4	10.2	21.73	73.91
646928	24	8.1	7.9	16.83	57.25
646929	24	15.7	15.5	33.02	112.32
646930	24	9.8	9.6	20.45	69.57
Group III					
646926	52	2.5	2.3	4.90	16.67
646927	52	1.7	1.5	3.20	10.87
646928	52	1.3	1.1	2.34	7.97
646929	52	4.0	3.8	8.09	27.54
646930	52	1.8	1.6	3.41	11.59
Group III					
646926	94	0.8	0.6	1.28	4.35
646927	94	<0.5	*	*	*
646928	94	<0.5	*	*	*
646929	94	0.9	0.7	1.49	5.07
646930	94	<0.5	*	*	*

* Below LOQ (Limit of Quantification)

Company Sanitized. Does not contain TSCA CBI

Data for H-25357

Given:

Mol Wt. Active (g/mole):	850000	% F in Active:	10
Formulation Dose (mg/kg):	1000	Mol Wt. F (g/mol):	19
% Active (F Containing) in Formulation:	19		

Calculated Values:

Dose Active (mg/kg):	190	Molar Ratio (Active/F):	2.2×10^{-4}
Dose Active (mmole/kg):	2.2×10^{-4}	Dose F (mg/kg):	19.0
Dose F (mmol/kg):	1.000		

Rat Number	Test Day Sample	ppm F in Blood	ppm F in Blood Minus Bkg 0.2 ppm	ppm F in Blood Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Blood
Group I					
665500	1	1.28	1.1	483.16	5.68
665501	1	1.02	0.8	366.84	4.32
665502	1	1.13	0.9	416.05	4.89
665503	1	1.02	0.8	366.84	4.32
665505	1	1.1	0.9	402.63	4.74
Group I					
665500	5	3.17	3.0	1328.68	15.63
665501	5	3.35	3.2	1409.21	16.58
665502	5	2.92	2.7	1216.84	14.32
665503	5	3.3	3.1	1386.84	16.32
665505	5	3.21	3.0	1346.58	15.84
Group I					
665500	10	2.71	2.5	1122.89	13.21
665501	10	3.31	3.1	1391.32	16.37
665502	10	2.79	2.6	1158.68	13.63
665503	10	2.92	2.7	1216.84	14.32
665505	10	2.64	2.4	1091.58	12.84

Rat Number	Test Day Sample	ppm F in Blood	ppm F in Blood Minus Bkg 0.2 ppm	ppm F in Blood Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Blood
Group III					
665506	13	2.3	2.1	939.47	11.05
665507	13	2.21	2.0	899.21	10.58
665508	13	2.44	2.2	1002.11	11.79
665509	13	2.52	2.3	1037.89	12.21
665510	13	1.86	1.7	742.63	8.74
Group III					
665506	24	2.64	2.4	1091.58	12.84
665507	24	2.72	2.5	1127.37	13.26
665508	24	1.33	1.1	505.53	5.95
665509	24	2.05	1.9	827.63	9.74
665510	24	2.68	2.5	1109.47	13.05
Group III					
665506	52	<.5	*	*	*
665507	52	<.5	*	*	*
665508	52	<.5	*	*	*
665509	52	<.5	*	*	*
665510	52	<.5	*	*	*
Group III					
665506	94	<.5	*	*	*
665507	94	<.5	*	*	*
665508	94	<.5	*	*	*
665509	94	<.5	*	*	*
665510	94	<.5	*	*	*

* Below LOQ (Limit of Quantification)

Company Sanitized. Does not contain TSCA CBI

APPENDIX E

Individual Fluorine Levels in Liver

Company Sanitized. Does not contain TSCA CBI

Data for H-24019

Given:

Mol Wt. Active (g/mole):	497	% F in Active:	65
Formulation Dose (mg/kg):	10	Mol Wt. F (g/mol):	19
% Active (F Containing) in Formulation:	100		

Calculated Values:

Dose Active (mg/kg):	10	Molar Ratio (Active/F):	0.059
Dose Active (mmole/kg):	0.020	Dose F (mg/kg):	6.5
Dose F (mmol/kg):	0.342		

Rat Number	Test Day Sample	ppm F in Liver	ppm F in Liver Minus Bkg 0.2 ppm	ppm F in Liver Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Liver
Group I					
646910	10	320.9	320.7	1593.88	4933.85
646911	10	334.0	333.8	1658.99	5135.38
646912	10	318.6	318.4	1582.45	4898.46
646913	10	281.6	281.4	1398.56	4329.23
646914	10	306.6	306.4	1522.81	4713.85
Group III					
646915	94	85.6	85.4	424.44	1313.85
646916	94	75.9	75.7	376.23	1164.62
646917	94	87.5	87.3	433.88	1343.08
646918	94	78.0	77.8	386.67	1196.92
646919	94	94.2	94.0	467.18	1446.15

Company Sanitized. Does not contain TSCA CBP

Data for H-24020

Given:

Mol Wt. Active (g/mole):	426	% F in Active:	69
Formulation Dose (mg/kg):	20	Mol Wt. F (g/mol):	19
% Active (F Containing) in Formulation:	100		

Calculated Values:

Dose Active (mg/kg):	20	Molar Ratio (Active/F):	0.065
Dose Active (mmole/kg):	0.047	Dose F (mg/kg):	13.8
Dose F (mmol/kg):	0.726		

Rat Number	Test Day Sample	ppm F in Liver	ppm F in Liver Minus Bkg 0.2 ppm	ppm F in Liver Normalized to 0.1 mmole/kg Dose	μmolar Equivalents of Active in Liver
Group I					
646921	10	118.3	118.1	251.55	855.80
646922	10	122.7	122.5	260.93	887.68
646923	10	114.3	114.1	243.03	826.81
646924	10	121.6	121.4	258.58	879.71
646925	10	122.1	121.9	259.65	883.33
Group III					
646926	94	1.8	1.6	3.41	11.59
646927	94	1.2	1.0	2.13	7.25
646928	94	2.2	2.0	4.26	14.49
646929	94	4.7	4.5	9.59	32.61
646930	94	2.9	2.7	5.75	19.57

Company Sanitized. Does not contain TSCA CBI

Data for H-25357

Given:

Mol Wt. Active (g/mole):	850000	% F in Active:	10
Formulation Dose (mg/kg):	1000	Mol Wt. F (g/mol):	19
% Active (F Containing) in Formulation:	19		

Calculated Values:

Dose Active (mg/kg):	190	Molar Ratio (Active/F):	2.2×10^{-4}
Dose Active (mmole/kg):	2.2×10^{-4}	Dose F (mg/kg):	19.0
Dose F (mmol/kg):	1.000		

Rat Number	Test Day Sample	ppm F in Liver	ppm F in Liver Minus Bkg 0.2 ppm	ppm F in Liver Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Liver
Group I					
665500	10	22.22	22.0	9851.05	115.89
665501	10	26.59	26.4	11806.05	138.89
665502	10	20.43	20.2	9050.26	106.47
665503	10	19.1	18.9	8455.26	99.47
665505	10	21.85	21.7	9685.53	113.95
Group III					
665506	94	1.84	1.6	733.68	8.63
665507	94	1.49	1.3	577.11	6.79
665508	94	1.36	1.2	518.95	6.11
665509	94	1.31	1.1	496.58	5.84
665510	94	1.61	1.4	630.79	7.42

Company Sanitized. Does not contain TSCA CBI

APPENDIX F

Individual Fluorine Levels in Fat

[Company Confidential. Does not contain TSCA CBI]

Data for H-24019

Given:

Mol Wt. Active (g/mole):	497	% F in Active:	65
Formulation Dose (mg/kg):	10	Mol Wt. F (g/mol):	19
% Active (F Containing) in Formulation:	100		

Calculated Values:

Dose Active (mg/kg):	10	Molar Ratio (Active/F):	0.059
Dose Active (mmole/kg):	0.020	Dose F (mg/kg):	6.5
Dose F (mmol/kg):	0.342		

Rat Number	Test Day Sample	ppm F in Fat	ppm F in Fat Minus Bkg 0.2 ppm	ppm F in Fat Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Fat
Group I					
646910	10	14.4	14.2	70.57	218.46
646911	10	14.9	14.7	73.06	226.15
646912	10	10.9	10.7	53.18	164.62
646913	10	11.6	11.4	56.66	175.38
646914	10	12.4	12.2	60.63	187.69
Group III					
646915	94	1.3	1.1	5.47	16.92
646916	94	1.1	0.9	4.47	13.85
646917	94	1.3	1.1	5.47	16.92
646918	94	0.8	0.6	2.98	9.23
646919	94	1.5	1.3	6.46	20.00

Company Sanitized. Does not contain TSCA CB1

Data for H-24020

Given:

Mol Wt. Active (g/mole):	426	% F in Active:	69
Formulation Dose (mg/kg):	20	Mol Wt. F (g/mol):	19
% Active (F Containing) in Formulation:	100		

Calculated Values:

Dose Active (mg/kg):	20	Molar Ratio (Active/F):	0.065
Dose Active (mmole/kg):	0.047	Dose F (mg/kg):	13.8
Dose F (mmol/kg):	0.726		

Rat Number	Test Day Sample	ppm F in Fat	ppm F in Fat Minus Bkg 0.2 ppm	ppm F in Fat Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Fat
Group I					
646921	10	6.2	6.0	12.78	43.48
646922	10	8.5	8.3	17.68	60.14
646923	10	8.7	8.5	18.11	61.59
646924	10	8.8	8.6	18.32	62.32
646925	10	8.3	8.1	17.25	58.70
Group III					
646926	94	ND	ND	ND	ND
646927	94	ND	ND	ND	ND
646928	94	ND	ND	ND	ND
646929	94	ND	ND	ND	ND
646930	94	ND	ND	ND	ND

ND Non-detectable.

Company Sanitized. Does not contain TSCA CB

Data for H-25357

Given:

Mol Wt. Active (g/mole):	850000	% F in Active:	10
Formulation Dose (mg/kg):	1000	Mol Wt. F (g/mol):	19
% Active (F Containing) in Formulation:	19		

Calculated Values:

Dose Active (mg/kg):	190	Molar Ratio (Active/F):	2.2×10^{-4}
Dose Active (mmole/kg):	2.2×10^{-4}	Dose F (mg/kg):	19.0
Dose F (mmol/kg):	1.000		

Rat Number	Test Day Sample	ppm F in Fat	ppm F in Fat Minus Bkg 0.2 ppm	ppm F in Fat Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Fat
Group I					
665500	10	23.06	22.9	10226.84	120.32
665501	10	24.36	24.2	10808.42	127.16
665502	10	18.3	18.1	8097.37	95.26
665503	10	15.85	15.7	7001.32	82.37
665505	10	23.73	23.5	10526.58	123.84
Group III					
665506	94	2.84	2.6	1181.05	13.89
665507	94	3.14	2.9	1315.26	15.47
665508	94	3.26	3.1	1368.95	16.11
665509	94	3.28	3.1	1377.89	16.21
665510	94	1.39	1.2	532.37	6.26

Company Sanitized. Does not contain TSCA CBI